Press release
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\n\nCiti’s 18th Annual BioPharma Conference – September 6, 2023\n\n\nType: 1-on-1 Investor Meetings\n\n\nEuropean Respiratory Society (ERS) International Congress – September 9-13, 2023\n\n\nDate: Sept. 10, 2023, 12:30-14:00 CEST\nType: Poster Session 146\nTitle: A Clinical-Stage Inhaled RNAi Therapeutic for Pulmonary Inflammation Mediates Durable RAGE Silencing in Nonhuman Primates\n\n\nDate: Sept. 10, 2023, 12:30-14:00 CEST\nType: Poster Session 146\nTitle: A Lung-Targeted RNAi Therapeutics Delivery Platform Compatible with Subcutaneous Administration Mediates Pulmonary RAGE Silencing in Rodents and Nonhuman Primates\n\n\nDate: Sept. 10, 2023, 12:30-14:00 CEST\nType: Poster Session 146\nTitle: Silencing TSLP Expression with a Lung-targeted RNAi Molecule Suppresses Pulmonary Allergic Inflammation\n\n\nDate: Sept. 11, 2023, 11:00-12:15 CEST\nType: Late Breaking Abstract\nTitle: A First-in-human Study of ARO-RAGE, an RNAi Therapy Designed to Silence Pulmonary RAGE Expression\n\n\nDate: Sept. 12, 2023, 8:00-9:30 CEST\nType: Poster Session 383\nTitle: A Clinical-stage RNAi Therapeutic Candidate for IPF Mediates Durable MMP7 Silencing in Nonhuman Primates and Human Lung Tissue\n\n\nBaird 2023 Global Healthcare Conference – September 12, 2023\n\n\nType: Fireside Chat Presentation\n\n\nMorgan Stanley 21st Annual Global Healthcare Conference – September 13, 2023\n\n\nType: Fireside Chat Presentation\n\n\n2023 Cantor Fitzgerald Global Healthcare Conference – September 27, 2023\n\n\nType: Fireside Chat Presentation\n\n\nWebcast links and presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\n\nAbout Arrowhead Pharmaceuticals\n\n\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a spec...